DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas2. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities3. High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma4. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma 5. Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma6. Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes7. Redefining the standard of care for low-grade serous ovarian cancer8. The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers9. The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific
